免疫学及免疫检测技术论文翻译.doc

Armed and accurate: engineering cytotoxic T cells for eradication of leukemia 装备并确认：工程细胞毒性T细胞 根除白血病 Marko Radic Correspondence: Marko Radic mradic@ Author Affiliations This is an Open Access article distributed under the terms of the Creative Commons Attribution License (HYPERLINK /licenses/by/2.0/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Translational medicine depends on a rapid and efficient exchange of results between the bench and the bedside. A recent example from the field of cancer immunotherapy highlights the essential nature of this exchange. Methods have been developed to convert a patients cytotoxic T cells into efficient and specific killers of cancer cells in patients with leukemia. By using recombinant DNA techniques, a lentiviral vector was constructed to express chimeric antigen receptors in cytotoxic T cells from patients with advanced chronic lymphocytic leukemia. The purpose of the chimeric receptors was to direct the cytotoxic T cell activity against cells causing the cancer. The effect of infusing the engineered T cells back into the cancer patients was tested in a Phase I trial at the University of Pennsylvania, and the initial results were described in two articles from the research team of Dr. Carl June. The remarkable success of this trial should energize further applications of biotechnology in the development of new cancer immunotherapies. 转化医学取决于工作台和病床间的快速，高效的转换的结果。最近的一个例子，从癌症的免疫疗法领域突出这种交换的本质。方法已被开发是将患者的细胞毒性T细胞转换成高效特异的癌细胞杀手。通过使用重组DNA技术，慢病毒载体构建从先进的慢性淋巴细胞白血病的患者的细胞毒性T细胞中表达嵌合抗原受体。嵌合受体的目的是指导细胞毒性T细胞对抗致癌细胞。I期临床试验在美国宾夕法尼亚大学设计的工程T细胞注入到癌症患者的影响进行了测试，卡尔博士的研究小组的两篇文章中描述了初步的结果。这项试验非凡的成功，应该激励在新的癌症免疫疗法的发展中进一步应用生物技术 Main Text Recent advances in cancer immunotherapy have allowed the conversion of T cells from leukemia patients into efficient and specific killers of their own cancer cells. The new technique has been recently tested with remarkable